Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2025 / Small Molecules / Christine Allen

Christine Allen

Professor, University of Toronto; Co-founder and CEO, Intrepid Labs

  • Profile

Meet Christine Allen

With a career spanning research and entrepreneurship, Christine’s work has helped advance the development of new drug delivery systems, including nanotechnologies and novel formulations that enhance the performance of therapies. Her integration of machine learning and robotics into drug formulation design has enabled a data-driven approach that minimizes reliance on traditional trial-and-error methods. She is also a fellow of the Canadian Academy of Health Sciences with more than 170 publications and numerous patents.

“For too long, we’ve accepted the high cost of R&D and the staggering failure rate in drug development. It doesn’t have to be this way. Technological advancements, such as AI, robotics, and data science, are transforming other industries. Why not us? We have an incredible opportunity to reimagine drug development, and we need to critically examine every stage of the drug development process to identify areas that are ripe for transformation.”

Recommended

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.